# Improving Early Reperfusion With Adjuvant Dornase Alfa in Large Vessel Ischemic Stroke (EXTEND-IA DNase)

> **NCT05203224** · PHASE2 · COMPLETED · sponsor: **University of Melbourne** · enrollment: 330 (actual)

## Conditions studied

- Ischemic Stroke

## Interventions

- **DRUG:** Dornase Alfa

## Key facts

- **NCT ID:** NCT05203224
- **Lead sponsor:** University of Melbourne
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-18
- **Primary completion:** 2025-11-24
- **Final completion:** 2026-02-25
- **Target enrollment:** 330 (ACTUAL)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05203224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05203224, "Improving Early Reperfusion With Adjuvant Dornase Alfa in Large Vessel Ischemic Stroke (EXTEND-IA DNase)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05203224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*